



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE)
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA
वाराणसी, उत्तर प्रदेश – २२१००५ / VARANASI, UTTAR PRADESH – 221005



Advt. No. HBCH/MPMMCC/PROJECT/2025/38

Date: 24.10.2025

WALK-IN INTERVIEW
Reporting time: 09:00 A.M. to 10:00 A.M.
(Project based vacancies)

Eligible and interested candidates are invited to attend the Walk-In Interview at Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U Campus, Varanasi, Uttar Pradesh – 221005. Candidates must bring Bio-data (Resume), Recent passport size photograph, PAN card, Aadhar card, Educational Certificates, Experience certificates in original and one set of self-attested copies, on the interview date(s).

(1)	Name of Post	Clinical Trial Coordinator
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 27.10.2025
	Monthly Remuneration:	Rs. 30,000/-
	Eligibility Criteria	Graduate degree in science with PG Diploma in Clinical Research. Experience of one year in relevant field is desirable.
	Upper Age Limit as on Walk-In Interview Date	45 years
	Project Name & A/c No.	Phase 3 study comparing TPF versus Paclitaxel- Carboplatin and oral metronomic chemotherapy as neoadjuvant chemotherapy for borderline resectable oral cancers. (Project A/c No. 160053)
(2)	Name of Post	Clinical Trial Coordinator
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 27.10.2025
	Monthly Remuneration:	Rs. 28,000/-
	Eligibility Criteria	Graduate degree in science with PG Diploma in Clinical Research. Experience of one year in relevant field is desirable.
	Project Name & A/c No.	IRetroBC-HER2L Study A Multicenter, Retrospective, Non interventional Study to Determine the Prevalence of HER2-low, Clinical Characteristics, Treatment Patterns, and Associated Outcomes in Patients Previously Identified With HER2 negative Locally-advanced or Metastatic Breast Cancer Who Progressed on Systemic Anticancer Therapy.(Project A/c No. 160005)
(3)	Name of Post	Clinical Trial Coordinator
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 27.10.2025
	Monthly Remuneration:	Rs. 25,000/-
	Eligibility Criteria	Graduate degree in science with PG Diploma in Clinical Research. Experience of one year in relevant field is desirable.
	Project Name & A/c No.	Phase III Randomized controlled trial of sequential chemotherapy and radiotherapy versus concurrent Chemoradiotherapy in adjuvant treatment of breast cancer.(Project A/c No. 160001)
(4)	Name of Post	Junior Research Fellow
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 27.10.2025
	Monthly Remuneration:	Rs. 23,000/-
	Eligibility Criteria	PG in life science with or without NET/GATE.
	Upper Age Limit as on Walk-In Interview Date	40 years
	Project Name & A/c No.	MicroRNA Profiling of Gallbladder Cancer (GBC) Cohort To Identify Biomarkers for Early Detection and Prognosis. (Project A/c No. 160023)



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE)
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA
वाराणसी, उत्तर प्रदेश - २२१००५ / VARANASI, UTTAR PRADESH - 221005



(5)	Name of Post	Research Assistant
	No. of Vacancy	02 (two)
	Walk-In Interview Date	Monday, 27.10.2025
	Monthly Remuneration:	Rs. 23,000/-
	Eligibility Criteria	Graduate degree in science.
	Upper Age Limit as on Walk-In Interview Date	30 years
	Project Name & A/c No.	Academic Fund (Project A/c No. 9299)

(6)	Name of Post	Data Entry Operator
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 27.10.2025
	Monthly Remuneration:	Rs. 21,000/-
	Eligibility Criteria	Graduate degree with a minimum six month computer course from a recognized institute or an MS-CIT certificate.
	Upper Age Limit as on Walk-In Interview Date	30 years
	Project Name & A/c No.	A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292). (Project A/c No. 9756)

Note:

1. The tenure will be valid for six months and may be extended further based on satisfactory performance and the institute's requirement.
2. In case of more candidates, Written Test will be conducted and eligible candidates will be shortlisted for the skill test / interview, accordingly.
3. All outstation candidates are required to make a note that accommodation will not be provided.

Administrative Officer III (HRD)